Introduction {#s1}
============

DNA reprogramming is essential for early embryonic development; around the time of implantation, *de novo* methylation is initiated in embryonic cells and is required for complete embryonic development (Li et al., [@B30]; Lei et al., [@B27]; Okano et al., [@B41]; Dean et al., [@B14]). In mammals, cytosine methylation is highly prevalent at CpG islands that modulate the chromatin structure and binding of transcriptional factors at promoter regions (Jaenisch and Bird, [@B24]). Thus, alterations in DNA methylation and epigenetic modification that occur during a specific window of gestational development can dysregulate gene expression and are associated with many diseases (Oberlander et al., [@B40]; Stein et al., [@B53]; Suter et al., [@B54]; Gore et al., [@B19]; Li et al., [@B29]; Perkins et al., [@B43]; West et al., [@B58]; Vanhees et al., [@B57]). Studies in humans and animal models have shown that variations in intake of the maternal nutrients involved in one-carbon metabolism, including folic acid (FA), during pregnancy can induce persistent changes in the offspring\'s epigenome and modulate various physiological outcomes (Cooney et al., [@B13]; Bean et al., [@B8]; Boeke et al., [@B10]; Greenop et al., [@B21]; [@B42]., [@B42]; Barua and Junaid, [@B5]). Our earlier studies in a mouse model had shown that exposure to high FA supplementation during gestation causes widespread changes in the methylation and gene expression in the cerebral hemisphere of the offspring (Barua et al., [@B6]). Moreover, such exposure during gestation and the post-weaning period resulted in moderate changes in behavior (Barua et al., [@B4]).

Over the past decades, several studies have shown that the cerebellum (CB) plays a significant role in coordination to motor functions and is involved in various cognitive processes, including perception, attention, and emotional behavior (Leiner et al., [@B28]; Martin et al., [@B33]; Schmahmann and Caplan, [@B50]). Recent studies with post-mortem brain samples have shown widespread aberrant methylation and gene expression in the CB of psychotic patients (Chen et al., [@B12]). Studies with a mouse model and in human post-mortem CB of individuals with autism have shown altered patterns of DNA methylation (Shpyleva et al., [@B51]), and indeed, cerebellar abnormalities have been reported in more than 95% of post-mortem examinations of individuals with autism (Marzban et al., [@B34]). To investigate whether higher supplementation with a methyl diet during gestation impacts the cerebellar development of offspring, in this study, we tested the hypothesis that higher folic acid supplementation during gestation can alter the methylation and gene expression in the CB of offspring.

Materials and methods {#s2}
=====================

Animals and experimental design
-------------------------------

All animal experiments were performed in accordance with protocols reviewed and approved by the Institute for Basic Research Institutional Animal Care and Use Committee in conformity with the NIH Guide for Care and Use of Laboratory Animals (NIH publication No. 86-23, revised 1985). One week prior to mating and throughout gestation, adult 8--10 week-old C57BL/6 J female mice were fed a custom AIN-93G amino acid--based diet (Research Diet, Inc., North Brunswick, NJ), having either low maternal folic acid (LMFA), at 0.4 mg/kg (*n* = 12), or high maternal folic acid (HMFA), at 4 mg/kg (*n* = 12). These levels of FA supplementation were chosen in this study, as women with a prior history of complicated and neural tube defect (NTD)--affected pregnancy are recommended to take 10-fold higher FA (4 mg/day) in comparison to other pregnant women (400--800 μg/day). FA at the 0.4 mg/kg diet level is necessary for a normal healthy litter, whereas FA at the 4 mg/kg diet level is 10 times higher.

Tissue collection and processing
--------------------------------

At post-natal day one (P1), pups from different dams were sacrificed, and CB tissues were dissected. The numbers of tissues collected from the LMFA group were: male pups, *n* = 15, and female pups *n* = 15. The numbers of tissues collected from the HMFA were: male pups *n* = 15, and female pups, *n* = 15. Tissues were immediately stored at −70°C until further use. From these, tissues were distributed for subsequent DNA/RNA and protein analysis.

DNA extraction
--------------

CB tissues were extracted from P1 pups and pooled (*n* = 3/gender/group, each from an independent dam). DNA was extracted with the Epicenter MasterPure DNA purification kit (Epicenter Biotechnologies, Madison, WI, USA) by following the manufacturer\'s instructions, and concentration was measured by using a NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE, USA).

Library construction, sequence alignments, and data analysis
------------------------------------------------------------

Library construction, sequence alignments, and data analysis were performed by following the detailed protocol previously described (Barua et al., [@B6]). Libraries were prepared from 200 to 500 ng of genomic DNA after sequential digestion with 60 units of TaqI and 30 units of MspI (New England Biolabs, Ipswich, MA, USA), and sequencing was performed on an Illumina HiSeq genome analyzer. Sequence reads from bisulfite-treated EpiQuest libraries were identified using standard Illumina base-calling software and then analyzed using a Zymo Research proprietary analysis pipeline, which is written in Python. Bismark (<http://www.bioinformatics.babraham.ac.uk/projects/bismark/>) was the alignment software in the analysis pipeline. Index files were constructed by *bismark_genome_preparation* command using the entire reference genome. --*non_directional* and all the other default parameters were applied for running Bismark. Filled-in nucleotides were trimmed off when doing methylation calling. The number of reads reporting a C was divided by the total number of reads reporting a C or T was used to estimate the methylation level of sample cytosine. For each CpG site, Fisher\'s exact test was performed, which covered at least five reads. Moreover, for each CpG promoter, gene body and CpG island annotations were added. The total numbers of reads that were taken into account for each CpG site are given in Tables [**2**](#T2){ref-type="table"}, [**3**](#T3){ref-type="table"}, and Tables [S1](#SM6){ref-type="supplementary-material"}--[S4](#SM9){ref-type="supplementary-material"} (column total CpG). All the procedures above were carried out in the Zymo Epigentic Core Services (Zymo Research, Irvine, CA). Sequence data has been deposited at the Sequence Read Archive (accession number [SRX1608467](SRX1608467)) in the National Center for Biotechnology Information (NCBI).

Quantitative real-time polymerase chain reaction (qPCR) analysis
----------------------------------------------------------------

Total RNA was extracted (*n* = 12, segregated by gender) by lysing the cells with Trizol reagent (Life Technologies, Inc., Carlsbad, CA) and was further purified by Qiagen RNeasy kit (Qiagen, Valencia, CA), according to the manufacturer\'s protocol as described earlier (Barua et al., [@B7]). For each sample, on-column DNase digestion was performed to remove any DNA contamination. Quantitative RT-PCR was performed with the One-Step iScript kit (BioRad, Hercules, CA) or the Two-step kit (Affymetrix, Santa Clara, CA) by following the manufacturer\'s instructions. *Hprt1* was used as the endogenous control, and the relative expression was calculated using the Pfaffl method. For each gene, the mRNA expression was measured from *n* = 3/gender/group, each from an independent dam. Each reaction was run in triplicates, and only the expression of those genes that exhibited the same directional changes in independent pools from at least two independent animals was considered significant. The statistical difference between samples was determined by Student\'s *t*-test by using Prism Software (GraphPad, San Diego, CA); values are presented as means ± standard deviation. Primers used for qRT-PCR are listed in Table [S5](#SM10){ref-type="supplementary-material"}.

Western blot analyses
---------------------

Total cell lysates (*n* = 16) from the CB of male (M) and female (F) pups were prepared from both the HMFA and the LMFA groups. For each of these two groups, four male CBs (each male pup from an independent dam) and four female CBs (each female pup from an independent dam), for a total eight pups were analyzed. Western blot analyses were done as previously described (Barua et al., [@B7]). Targeted proteins were detected by incubating with primary antibodies overnight at 4°C (dilutions for anti-GAD1 1:500 and anti-PARK2 1:200) followed by the secondary antibody coupled with horseradish peroxidase. Densitometric evaluation of the bands was calculated by using ImageJ software (NIH) and was normalized to the densities of β-actin staining as housekeeping control. The average calculated ratios of target protein to β-actin are presented.

Results {#s3}
=======

Global DNA methylation patterns of the offspring\'s CB from HMFA
----------------------------------------------------------------

The statistics of the mapping of the methylation profiles of pups CB\'s of pups from mothers supplemented with LMFA and HMFA are given in Table [1](#T1){ref-type="table"}. The ratio of mapped reads to total reads ranged from 40 to 46.34% in male pups and from 56.87 to 61.33% in female pups from the LMFA and HMFA groups, respectively, with an average depth of CpG coverage (12x--13x) in males and (10x--16x) in females. The bisulfate conversion rates were approximately 98% for all the samples. Analysis of the global methylation profile revealed that 19% of the CpG sites were differentially methylated in pups from the HMFA group in comparison to that of the LMFA group in both male and female pups (*n* = 40.376 for male and *n* = 44.974 for female). Moreover, the majority of differentially methylated regions (DMRs) were in the intergenic or introns, whereas 19--20% were in exons, and 8--9% were in the promoter regions in the CpG-island sequence (Figures [S1A,B](#SM1){ref-type="supplementary-material"}). Similar to the CpG sites, the distribution of DMRs in the non-CpG sites revealed that the majority of DMRs were in the intergenic or introns, whereas 9--10% in exons, and 15--23% in the promoter regions (Figure [S2](#SM2){ref-type="supplementary-material"}). The distribution of methylation ratios and the Pearson\'s correlation coefficient for the corresponding CpG and non-CpG sites of male and female pups are shown in Figures [S3](#SM3){ref-type="supplementary-material"}, [S4](#SM4){ref-type="supplementary-material"}. The hexbin plot (Figures [S5](#SM5){ref-type="supplementary-material"}--[S7](#SM7){ref-type="supplementary-material"}) shows the distribution of overlapped CpG and non-CpG sites (*P* \< 0.05) in male and female pups as a result of HMFA. The result of global DNA methylation profiling indicated that HMFA altered the methylation pattern of the epigenome of the offspring\'s CB.

###### 

**Descriptive statistics of the mapping of methylation profile of pups\' cerebellums from mothers supplemented with FA at 0.4 (LMFA) and 4 mg/kg (HMFA)**.

  **Cerebellum**   **Total read**   **Mapped read**   **Mapping ratio (%)**   **Unique CpG**   **CpG Cov. (X)**   **BS conv. rate (%)**
  ---------------- ---------------- ----------------- ----------------------- ---------------- ------------------ -----------------------
  CB-04 Male       29,885,144       13,848,250        46.34                   4,430,390        12                 98.09
  CB-4 Male        29,016,284       11,607,234        40.00                   3,348,964        13                 98.70
  CB-04 Female     37,174,068       21,140,555        56.87                   4,643,308        16                 98.59
  CB-4 Female      17,432,488       10,690,857        61.33                   3,784,838        10                 98.78

Maternal FA alters DNA methylation status of several genes in the CpG and non-CpG sites in offspring\'s CB
----------------------------------------------------------------------------------------------------------

DNA methylation analysis at the single base level revealed that HMFA resulted in significant alterations in the methylation level of several genes. The alterations of methylation level were found in both CpG and non-CpG (CHG, CHH) sites throughout the entire genome in both male and female pups from HMFA group (Figures [S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}). Such alterations were evident both in promoter and gene body regions and resulted in either hyper-methylation or hypo-methylation (*P* ≤ 0.05) in pups supplemented with HMFA. Multiple testing corrections revealed that HMFA resulted in hyper-methylation (Table [2](#T2){ref-type="table"}) of several genes that modulate neuronal pathways in male pups (*Atp1a1, Kcnq4, Bre, Scnn1a, Celsr3, Kcnk10*), whereas the methylation of a gene of the neurexin gene family (*Nrxn2*) was hyper-methylated in female pups. Further analysis of methylation data revealed significant hypo-methylation (Table [3](#T3){ref-type="table"}) of several genes in both male and female pups from the HMFA group. Several genes related to intellectual disability (*Dcaf17, Myst4, Park2, Rbfox1*) were found to be hypo-methylated in male pups, and genes (*Pfn1, Cntnap1, Drp2*) related to normal function of the nervous system were hypo-methylated in female pups from the HMFA group. Transcriptional factors in male pups (*Gtf2i, Nr3c2*) and in female pups (*Foxl2, Rfx1*) were hyper-methylated, whereas transcriptional factor *Rn45s* was hypo-methylated in female pups. Of note, the methylation level of sidekick cell adhesion molecule 1 (*Sdk1*) was hyper-methylated in both male and female pups from the HMFA group.

###### 

**List of hypermethylated CpG/CHH/CHG sites in the gene body/promoter/other chromosomal region of genes from high maternal folic acid diet that were significantly altered after multiple testing corrections**.

  **Chromosome**                                                          **Start**   **End**     **Gene**                                         **Total CpG LMFA**   **Total CpG HMFA**   **Methylation difference**   ***P-*value**   **Adj *P-*value**
  ----------------------------------------------------------------------- ----------- ----------- ------------------------------------------------ -------------------- -------------------- ---------------------------- --------------- -------------------
  **MALE**                                                                                                                                                                                                                                
  **CpG**                                                                                                                                                                                                                                 
  Chr3                                                                    101396425   101396426   *Atp1a1*                                         48                   55                   0.69                         4.73043E-11     8.61543E-06
  Chr4[^a^](#TN2){ref-type="table-fn"}                                    120370725   120370726   *Kcnq4*                                          38                   18                   0.73                         5.23985E-08     0.000602429
  Chr5                                                                    32310326    32310327    *Bre*                                            8                    16                   1.00                         1.35967E-06     0.00766814
  Chr5[^a^](#TN2){ref-type="table-fn"}                                    122872838   122872839   *Anapc7*                                         20                   11                   0.90                         9.21198E-07     0.005834628
  Chr6[^a^](#TN2){ref-type="table-fn"}                                    99642691    99642692    *Gpr27*                                          46                   10                   0.80                         2.59437E-06     0.012370994
  Chr6                                                                    125280040   125280041   *Scnn1a*                                         21                   33                   0.68                         8.58529E-08     0.000857291
  Chr7                                                                    29537833    29537834    *Sars2*                                          17                   17                   0.76                         5.1294E-06      0.020249774
  Chr8                                                                    79656982    79656983    *Nr3c2*                                          30                   24                   0.68                         2.79663E-07     0.002218414
  Chr9                                                                    108751023   108751024   *Celsr3*                                         32                   20                   0.70                         4.85931E-07     0.003592574
  Chr11[^a^](#TN2){ref-type="table-fn"}                                   4962328     4962329     *Gas2l1*                                         14                   18                   0.89                         5.09083E-07     0.003724971
  Chr12                                                                   3739974     3739975     *Dtnb*                                           15                   20                   0.77                         1.10085E-05     0.034438481
  Chr12[^a^](#TN2){ref-type="table-fn"}                                   52930473    52930474    *Hectd1*                                         31                   11                   0.91                         7.47565E-09     0.000114327
  Chr12                                                                   83903228    83903229    *Rgs6*                                           28                   41                   0.71                         2.68793E-11     8.35061E-06
  Chr12                                                                   99800383    99800384    *Kcnk10*                                         14                   32                   0.69                         9.50913E-06     0.03190158
  ChrX                                                                    110293664   110293665   *Chm*                                            6                    24                   1.00                         1.68414E-06     0.008878596
  **CHH**                                                                                                                                                                                                                                 
  Chr3                                                                    37380544    37380545    *Spata5*                                         10                   16                   1.00                         1.88262E-07     0.018712081
  Chr3                                                                    37379114    37379115    *Spata5*                                         39                   54                   0.52                         4.92021E-09     0.000825025
  Chr5[^a^](#TN2){ref-type="table-fn"}                                    122872790   122872791   *Anapc7*                                         57                   38                   0.71                         2.29993E-11     5.49912E-05
  Chr5                                                                    129289390   129289391   *Rimbp2*                                         22                   42                   0.62                         3.47908E-07     0.031282409
  Chr5                                                                    142522151   142522152   *Sdk1*                                           41                   52                   0.49                         2.95614E-07     0.027788529
  Chr8                                                                    34944721    34944722    *Rbpms*                                          33                   40                   0.59                         1.33163E-07     0.013543758
  Chr11                                                                   89851744    89851745    *Pctp*                                           46                   39                   0.52                         6.98215E-08     0.007876096
  Chr17                                                                   81118969    81118970    *Map4k3*                                         20                   36                   0.72                         6.36563E-08     0.007313615
                                                                                                                                                                                             0.00                                         
  **CHG**                                                                                                                                                                                    0.00                                         
  Chr4                                                                    108146626   108146627   *Zcchc11*                                        112                  115                  0.34                         5.53559E-08     0.006775161
  Chr5                                                                    134721807   134721808   *Gtf2i*                                          57                   80                   0.49                         9.5847E-11      7.42648E-05
  Chr5                                                                    73446765    73446766    *Fryl*                                           64                   49                   0.44                         1.56966E-08     0.002561524
  Chr8                                                                    34914184    34914185    *Rbpms*                                          34                   62                   0.52                         3.10146E-08     0.004794897
  **FEMALE**                                                                                                                                                                                                                              
  **CpG**                                                                                                                                                                                                                                 
  Chr2                                                                    18865431    18865432    *Pip4k2a*                                        14                   8                    1.00                         3.12725E-06     0.017610194
  Chr4                                                                    150525065   150525066   *Camta1*                                         17                   14                   0.81                         6.84434E-06     0.032886803
  Chr7                                                                    133845071   133845072   *Coro1a*                                         89                   14                   0.70                         5.12126E-07     0.003733256
  Chr8                                                                    86608595    86608596    *Rfx1*                                           45                   12                   0.70                         9.53995E-06     0.042482671
  Chr8[^\*^](#TN1){ref-type="table-fn"}                                   86608595    86608596    ***Mir709***[^\*^](#TN1){ref-type="table-fn"}    45                   12                   0.70                         9.53995E-06     0.042482671
  Chr10                                                                   79397201    79397202    *Arid3a*                                         29                   14                   0.93                         1.53102E-09     1.95146E-05
  Chr10                                                                   60250203    60250204    *Unc5b*                                          25                   18                   0.70                         5.43229E-06     0.027663076
  Chr11                                                                   102139305   102139306   *Asb16*                                          34                   19                   0.68                         1.40228E-06     0.009072618
  Chr14                                                                   52609319    52609320    *Arhgef40*                                       42                   8                    0.90                         9.21996E-07     0.006230346
  Chr14[^\*^](#TN1){ref-type="table-fn"}                                  52609319    52609320    ***Gm16617***[^\*^](#TN1){ref-type="table-fn"}   42                   8                    0.90                         9.21996E-07     0.006230346
  Chr16                                                                   10979333    10979334    *Litaf*                                          38                   10                   0.95                         1.00906E-08     0.00011098
  Chr17[^a^](#TN2){ref-type="table-fn"}                                   39985399    39985400    *Rn45s*                                          20                   11                   0.90                         9.21198E-07     0.006230346
  Chr18                                                                   75697791    75697792    *Ctif*                                           58                   11                   0.74                         5.0559E-06      0.025932481
  Chr19[^a^](#TN2){ref-type="table-fn"}                                   6428759     6428760     *Nrxn2*                                          52                   10                   0.72                         5.74263E-06     0.028897735
  ChrX[^a^](#TN2){ref-type="table-fn"}                                    137133982   137133983   *Tsc22d3*                                        39                   8                    0.95                         1.43104E-07     0.001162634
  ChrX[^a^](#TN2){ref-type="table-fn"}[^\*^](#TN1){ref-type="table-fn"}   53984977    53984978    ***Fhl1***[^\*^](#TN1){ref-type="table-fn"}      46                   14                   0.83                         1.84349E-08     0.000189568
  ChrX[^a^](#TN2){ref-type="table-fn"}[^\*^](#TN1){ref-type="table-fn"}   160346929   160346930   ***Ap1s2***[^\*^](#TN1){ref-type="table-fn"}     52                   10                   0.72                         5.74263E-06     0.028897735
  **CHH**                                                                                                                                                                                                                                 
  Chr19[^a^](#TN2){ref-type="table-fn"}                                   46072916    46072917    *9130011E15Rik*                                  61                   6                    1.00                         1.00205E-08     0.00773454
  **CHG**                                                                                                                                                                                                                                 
  Chr9                                                                    57880963    57880964    *Ccdc33*                                         53                   6                    1.00                         2.21939E-08     0.012821301
  Chr9[^a^](#TN2){ref-type="table-fn"}                                    98856591    98856592    *Foxl2*                                          102                  11                   0.64                         8.54473E-09     0.006910752
  Chr9[^a^](#TN2){ref-type="table-fn"}[^\*^](#TN1){ref-type="table-fn"}   98856591    98856592    ***Foxl2os***[^\*^](#TN1){ref-type="table-fn"}   102                  11                   0.64                         8.54473E-09     0.006910752
  Chr19[^a^](#TN2){ref-type="table-fn"}                                   37625255    37625256    *Exoc6*                                          66                   8                    0.97                         2.98577E-09     0.003018518
  **OTHER CHROMOSOMAL REGIONS**                                                                                                                                                                                                           
  **MALE**                                                                                                                                                                                                                                
  **CpG**                                                                                                                                                                                                                                 
  Chr2                                                                    117020483   117020484                                                    19                   23                   0.72                         5.75229E-06     0.022192691
  Chr4                                                                    55291226    55291227                                                     24                   17                   0.69                         1.55743E-05     0.044508695
  Chr6                                                                    122591925   122591926                                                    17                   23                   0.71                         1.1076E-06      0.006597209
  Chr10                                                                   92819632    92819633                                                     16                   31                   0.81                         3.98075E-09     7.03909E-05
  Chr12                                                                   110057962   110057963                                                    16                   31                   0.75                         8.42303E-07     0.00545744
  Chr14                                                                   87019484    87019485                                                     14                   26                   0.78                         1.29013E-06     0.007324618
  Chr17                                                                   80418706    80418707                                                     31                   23                   0.75                         5.72815E-09     9.24604E-05
  Chr17                                                                   80418649    80418650                                                     31                   23                   0.74                         2.14082E-09     4.08331E-05
  Chr17                                                                   80418656    80418657                                                     31                   23                   0.74                         2.14082E-09     4.08331E-05
  Chr17                                                                   80418710    80418711                                                     31                   22                   0.73                         5.02628E-09     8.44787E-05
  Chr17                                                                   80418721    80418722                                                     28                   23                   0.70                         1.02512E-07     0.000977631
  Chr17                                                                   49319822    49319823                                                     18                   47                   0.68                         8.1497E-07      0.005341511
  Chr18                                                                   8736817     8736818                                                      32                   9                    0.81                         1.4286E-05      0.04188451
  Chr18                                                                   8736774     8736775                                                      31                   9                    0.81                         1.83039E-05     0.048931908
  Chr18                                                                   60275673    60275674                                                     14                   22                   0.71                         3.93805E-06     0.017229446
  **CHH**                                                                                                                                                                                                                                 
  Chr3                                                                    37105839    37105840                                                     28                   60                   0.50                         4.59752E-07     0.039616449
  Chr8                                                                    32211528    32211529                                                     45                   70                   0.57                         5.4005E-11      5.49912E-05
  Chr8                                                                    29104849    29104850                                                     30                   44                   0.55                         1.11592E-07     0.011734506
  Chr8                                                                    27826273    27826274                                                     36                   48                   0.51                         5.73672E-07     0.0474555
  Chr17                                                                   85245770    85245771                                                     36                   62                   0.68                         9.22107E-11     5.49912E-05
  **CHG**                                                                                                                                                                                                                                 
  Chr3                                                                    18872260    18872261                                                     69                   40                   0.45                         6.79721E-10     0.000153587
  Chr9                                                                    4249915     4249916                                                      41                   86                   0.53                         5.27759E-10     0.000129188
  **FEMALE**                                                                                                                                                                                                                              
  **CpG**                                                                                                                                                                                                                                 
  Chr3                                                                    15582599    15582600                                                     64                   28                   0.73                         3.54618E-11     1.16245E-05
  Chr7                                                                    142676163   142676164                                                    50                   6                    0.92                         6.46782E-06     0.03164917
  Chr7                                                                    140397403   140397404                                                    46                   20                   0.67                         2.57852E-07     0.001995863
  Chr11                                                                   116362692   116362693                                                    50                   6                    0.96                         8.62376E-07     0.005883499
  ChrX                                                                    139577966   139577967                                                    8                    18                   0.76                         0.000397497     0.506460372
  ChrX                                                                    118333137   118333138                                                    44                   13                   0.68                         8.19276E-06     0.037584248
  **CHH**                                                                                                                                                                                                                                 
  Chr8                                                                    114228185   114228186                                                    43                   6                    1.00                         7.15112E-08     0.047312275
  **CHG**                                                                                                                                                                                                                                 
  Chr18                                                                   83201037    83201038                                                     70                   12                   0.67                         1.38883E-08     0.009360419

Methylation exclusively in the CpG island;

Methylation in the promoter regions; HMFA, high maternal folic acid; LMFA, low maternal folic acid. CHH, CHG where H can be A, T or G.

###### 

**List of hypomethylated CpG/CHH/CHG sites in the gene body/promoter/other chromosomal region of genes from high maternal folic acid diet that were significantly altered after multiple testing corrections**.

  **Chromosome**                          **Start**   **End**     **Gene**          **Total CpG**   **Total CpG**   **Methylation**   ***P-*value**   **Adj *P-*value**
  --------------------------------------- ----------- ----------- ----------------- --------------- --------------- ----------------- --------------- -------------------
  **MALE**                                                                                                                                            
  **CpG**                                                                                                                                             
  Chr2                                    70926781    70926782    *Dcaf17*          12              8               −1.00             7.9384E-06      0.028133219
  Chr3                                    51477712    51477713    *Mgst2*           16              15              −0.73             1.6121E-05      0.045534315
  Chr5                                    111715613   111715614   *Ttc28*           46              19              −0.79             1.95557E-09     3.9055E-05
  Chr10                                   79393579    79393580    *Arid3a*          18              12              −0.83             2.1967E-06      0.010935514
  Chr11                                   69574236    69574237    *Amac1*           42              15              −0.80             2.10416E-08     0.000279056
  Chr11                                   89384648    89384649    *Ankfn1*          16              19              −0.74             9.65017E-06     0.032243587
  Chr12                                   109176310   109176311   *Bcl11b*          10              31              −0.77             1.73473E-05     0.04752513
  Chr13                                   24228093    24228094    *Lrrc16a*         13              16              −0.86             3.07969E-06     0.014240168
  Chr17                                   11729485    11729486    *Park2*           10              10              −1.00             1.08251E-05     0.034194413
  **CHH**                                                                                                                                             
  Chr5                                    150366342   150366343   *Wdr95*           27              32              −0.85             1.21698E-12     7.55036E-06
  Chr6                                    119463258   119463259   *Wnt5b*           16              43              −0.69             1.56071E-08     0.002104991
  Chr8                                    119603496   119603497   *Pkd1l2*          25              56              −0.60             7.02256E-09     0.001146559
  Chr9                                    107166117   107166118   *Mapkapk3*        24              39              −0.65             2.17476E-07     0.020757812
  Chr16                                   6736334     6736335     *Rbfox1*          26              36              −0.71             4.2963E-09      0.000740418
                                                                                                                    0.00                              
  **CHG**                                                                                                           0.00                              
  Chr4                                    43744421    43744422    *5430416O09Rik*   38              79              −0.66             1.89728E-11     4.03799E-05
  Chr9                                    103033308   103033309   *Rab6b*           23              37              −0.65             9.21745E-09     0.00159268
  Chr9                                    104021165   104021166   *Acad11*          38              72              −0.58             2.74934E-11     4.03799E-05
  Chr11                                   118130307   118130308   *Usp36*           38              51              −0.55             2.20911E-10     7.42648E-05
  Chr16                                   15797072    15797073    *Prkdc*           8               26              −1.00             5.50776E-08     0.006775161
  **FEMALE**                                                                                                                                          
  **CpG**                                                                                                                                             
  Chr1[^a^](#TN3){ref-type="table-fn"}    39592922    39592923    *D1Bwg0212e*      46              12              −0.72             7.29815E-06     0.034293206
  Chr2                                    54854875    54854876    *Galnt13*         40              10              −0.85             7.79574E-07     0.005370225
  Chr3                                    152572664   152572665   *St6galnac5*      46              10              −0.76             1.32097E-06     0.008651764
  Chr5                                    150883968   150883969   *Rxfp2*           52              6               −0.92             5.18834E-06     0.026484159
  Chr5                                    4009104     4009105     *Akap9*           47              8               −0.87             2.4664E-06      0.014583234
  Chr7                                    13564506    13564507    *Zfp446*          17              6               −1.00             9.90619E-06     0.043500018
  Chr7                                    142277612   142277613   *Dock1*           49              15              −0.71             2.05041E-08     0.000206849
  Chr8[^a^](#TN3){ref-type="table-fn"}    73985459    73985460    *Abhd8*           66              11              −0.76             1.60125E-06     0.01005433
  Chr9                                    45614148    45614149    *Cep164*          41              15              −0.80             8.14852E-10     1.23014E-05
  Chr9                                    65575164    65575165    *Zfp609*          35              8               −0.75             4.59283E-06     0.024030758
  Chr11                                   100924353   100924354   *Atp6v0a1*        40              6               −0.95             2.98928E-06     0.016967907
  Chr11                                   63783989    63783990    *Cox10*           24              12              −0.92             7.27024E-08     0.00063948
  Chr11                                   118386794   118386795   *Rbfox3*          33              10              −0.82             4.17663E-06     0.02232177
  Chr11                                   70466348    70466349    *Pfn1*            71              18              −0.75             3.48721E-09     4.17015E-05
  Chr11                                   101045277   101045278   *Cntnap1*         84              16              −0.71             4.67003E-08     0.00043033
  Chr13                                   115629726   115629727   *Itga2*           52              14              −0.70             1.73075E-06     0.010740731
  Chr15                                   73386877    73386878    *Dennd3*          42              6               −0.95             2.28171E-06     0.013758747
  Chr15                                   76684078    76684079    *Zfp251*          43              7               −0.71             9.91146E-06     0.043500018
  Chr17                                   26145026    26145027    *Rab11fip3*       35              6               −1.00             2.22401E-07     0.00174687
  Chr17                                   34201190    34201191    *Col11a2*         69              10              −0.71             4.42664E-06     0.023265511
  Chr18                                   64349640    64349641    *1700091E21Rik*   60              8               −0.72             6.76961E-06     0.032675219
  ChrX                                    130978215   130978216   *Drp2*            42              6               −0.95             2.28171E-06     0.013758747
  **CHG**                                                                                                                                             
  Chr17[^a^](#TN3){ref-type="table-fn"}   39981459    39981460    *Rn45s*           215             1801            −0.32             3.15966E-11     0.000127773
  **OTHER CHROMOSOMAL REGIONS**                                                                                                                       
  **MALE**                                                                                                                                            
  **CpG**                                                                                                                                             
  Chr4                                    114927822   114927823                     19              16              −1.00             2.4631E-10      1.6251E-05
  Chr4                                    70356713    70356714                      11              8               −1.00             1.32307E-05     0.039611439
  Chr4                                    33145068    33145069                      22              23              −0.74             1.15388E-07     0.001082193
  Chr6                                    22702718    22702719                      20              38              −0.79             1.68255E-09     3.40026E-05
  Chr8                                    23561782    23561783                      10              9               −1.00             1.08251E-05     0.034194413
  Chr8                                    125951782   125951783                     6               15              −1.00             1.84284E-05     0.049033126
  Chr8                                    15641954    15641955                      33              10              −0.87             1.72635E-07     0.001510603
  Chr9                                    49862607    49862608                      10              10              −1.00             1.08251E-05     0.034194413
  Chr10                                   12602192    12602193                      17              8               −1.00             9.24578E-07     0.005834628
  Chr10                                   123989391   123989392                     17              35              −0.83             4.59988E-09     7.96787E-05
  Chr12                                   44576005    44576006                      19              14              −0.80             3.041E-06       0.014104497
  Chr12                                   68850704    68850705                      31              14              −0.76             1.20506E-06     0.007029716
  Chr14                                   13972178    13972179                      44              9               −0.84             4.38892E-07     0.003296639
  Chr15                                   31799762    31799763                      14              16              −0.81             4.79293E-06     0.019439463
  Chr16                                   55473911    55473912                      24              11              −0.78             1.52675E-05     0.043927676
  Chr17                                   84101994    84101995                      10              10              −1.00             1.08251E-05     0.034194413
  Chr17                                   40509054    40509055                      26              26              −0.73             1.66363E-07     0.001486366
  **CHH**                                                                                                                                             
  Chr4                                    62532417    62532418                      30              18              −0.80             3.6826E-08      0.004662758
  Chr16                                   39097237    39097238                      47              34              −0.70             4.56498E-11     5.49912E-05
  Chr18                                   53985910    53985911                      27              30              −0.63             6.04117E-08     0.007071799
  **CHG**                                                                                                                                             
  Chr4                                    44486603    44486604                      24              72              −0.53             1.53357E-07     0.017325988
  Chr8                                    97707113    97707114                      31              43              −0.52             4.46831E-08     0.006250153
  Chr8                                    91367262    91367263                      39              56              −0.46             5.61123E-09     0.001030159
  Chr10                                   93725790    93725791                      84              53              −0.46             1.1065E-10      7.42648E-05
  Chr11                                   101785985   101785986                     26              44              −0.54             4.99742E-08     0.006672518
  **FEMALE**                                                                                                                                          
  **CpG**                                                                                                                                             
  Chr1                                    72001078    72001079                      32              8               −0.75             7.29474E-06     0.034293206
  Chr2                                    178977613   178977614                     52              10              −0.88             7.44799E-08     0.000649745
  Chr3                                    69055711    69055712                      66              8               −0.85             2.90337E-06     0.016568628
  Chr5                                    48149488    48149489                      54              10              −0.80             1.01668E-08     0.00011098
  Chr7                                    76060069    76060070                      43              10              −0.77             9.4751E-06      0.042282364
  Chr8                                    4203056     4203057                       66              6               −0.91             5.91402E-06     0.029620167
  Chr8                                    66000281    66000282                      61              8               −0.72             6.1866E-06      0.030412915
  Chr16                                   22049549    22049550                      26              14              −0.71             1.1809E-06      0.007855174
  Chr18                                   83282753    83282754                      95              9               −0.83             9.90991E-08     0.000823993
  Chr18                                   67611225    67611226                      62              10              −0.74             9.90604E-06     0.043500018
  Chr19                                   45266101    45266102                      30              18              −0.80             3.6826E-08      0.00034839

Methylation exclusively in the CpG island; HMFA, high maternal folic acid; LMFA, low maternal folic acid. CHH, CHG where H can be A, T or G.

Further analysis of all *P* ≤ 0.05 differential methylation sites without correction for multiple testing identified several genes that were hyper-methylated or hypo-methylated in male and female pups, in both the CpG and non-CpG sites (Tables [S1](#SM6){ref-type="supplementary-material"}--[S4](#SM9){ref-type="supplementary-material"}). The methylation level of genes associated with autism spectrum disorder (*Plxna4, Arid1b, Kdm4c, Runx1, Accn1, Aff2, Chd9, Cntnap2, Grip1, Grin2b*, and *Mid1*); imprinted genes (*Peg12, Tsix*); transcriptional factors (*Ebf2, Lmx1b, Runx3, Sox13*, and *Mef2a*) that modulate neurogenesis; and genes related to neurodevelopment (*Grik4, Ntrk2, Sgk1, Cacna1a, Gabrg3, Erbb3*, and *Gfra1*) were found to be altered in CB of both male and female pups from the HMFA group. Our findings suggest that maternal diet during gestation, specifically HMFA, can modulate the methylation profile of several genes, including those involved in neural development in the gene bodies and the promoter, CpG, and non-CpG sites in the CB of pups\' brains.

Maternal FA alters expression of several differentially methylated genes in offspring\'s CB
-------------------------------------------------------------------------------------------

To extend our findings, we then analyzed whether HMFA induced changes in the overall methylation profile in offspring\'s CB correlates with the alterations in gene expression. Quantitative RT-PCR analysis of several genes that showed differential methylation (*P* ≤ 0.05) exhibited variations in expression in pups from the HMFA group. Genes in male pups from the HMFA group that exhibited significant hyper-methylation after multiple testing corrections in CpG sites (*Atp1a1, Bre, Celsr3, Kcnq4*) and *Gtf2i* in CHG sites did not exhibit any changes in expression level compared to pups from the LMFA group (Figure [1A](#F1){ref-type="fig"}). In contrast, expression of *Kcnk10*, a gene that encodes protein from the potassium channel family and is hyper-methylated in CpG sites, was significantly down-regulated in male pups from the HMFA group (Figure [1A](#F1){ref-type="fig"}). In female pups from the HMFA group, genes that exhibited hyper-methylation in CpG sites after multiple corrections (*Arid3a, Nrxn2, Unc5b*) exhibited no significant change in expression, whereas the expression of *Coro1a* was up-regulated significantly (Figure [1B](#F1){ref-type="fig"}). Similarly, analysis of expression of genes that were hypo-methylated at CpG sites by HMFA revealed significant up-regulation in expression of *Arid3a* in male pups whereas the expression of several other genes in male (*Dcaf17, Park2, Rbfox1*) and in female (*Col11a2, Cox10, Drp2, Itga2, Pfn1*, and *Rxfp2*) pups did not exhibit any significant changes (Figures [1C,D](#F1){ref-type="fig"}).

![**Relative expression of the genes that exhibited hyper-methylation (A,B) and hypo-methylation (C,D)**. The results were normalized to *Hprt* transcript expression and were expressed as relative values in comparison with corresponding transcripts from low maternal folic acid (LMFA). Results represent mean ± standard deviation (SD); asterisks denote statistically significant change (^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001).](fnins-10-00168-g0001){#F1}

To further reveal the impact of maternal FA, we next assessed whether HMFA-induced changes of methylation (*P* ≤ 0.05, without corrections) alter the expression of genes related to neuronal pathways (Figures [1A--D](#F1){ref-type="fig"}). Our results showed significant down-regulation in the expression of genes (*Gfra1, Plxna4, and Grin2b*), up-regulation in the expression of genes (*Grik4, Cacna1g, Dock4, Unc5b*, and *Gabrr1*), and no changes in the expression level of genes (*Ntrk2, Cacna1a*) in male pups that exhibited hyper-methylation at CpG or non-CpG sites (Figure [1A](#F1){ref-type="fig"}). In female pups from the HMFA group, several genes that were hyper-methylated at CpG or non-CpG sites also exhibited changes in expression level (Figure [1B](#F1){ref-type="fig"}).

Although the expression of some genes (*Gfra1, Gabrg3*) was down-regulated and of other genes (*Cntnap2, Grin2b, Sgk1, Gad1, Grip1, Kcnb1*, and *Slc25a12*) was up-regulated, the expression of some other genes (*Mid1, Ntrk2, Park2, Cacna1a, Park2, and Kcnq1*) was unaltered. Similarly, expression analysis of genes that exhibited hypo-methylation (*P* ≤ 0.05, without corrections) in CpG and non-CpG sites revealed down-regulation in the expression of genes in male (*Sgk1, Myst4, Gabrg3*) and in female (*Gfra1, Runx1*) pups (Figures [1C,D](#F1){ref-type="fig"}). HMFA resulted in up-regulation in the expression of some genes in male (*Gabrb1, Kcnab2, Kcnq1, Scn8a, Mid1, Cntnap2, Cox10*) and in female (*Grik4, Fmr1, Kcnq2*) pups, whereas the expression of other genes in male (*Runx1, Grip1*) and in female (*Plxna4, Dnmt1*) pups remained unaltered (Figures [1C,D](#F1){ref-type="fig"}).

Maternal FA down-regulates expression of gad1p in offspring\'s CB
-----------------------------------------------------------------

Next, we analyzed whether the expression of two genes (*Gad1*, hyper-methylated at CpG in female pups and *Park2*, hyper- and hypo-methylated at both CpG and non-CpG sites in male and female pups) that play a role in neuronal pathways including autism are altered at the protein level. Western blot analysis and densitometric quantification of the protein levels revealed that the expression of Gad1p (Figure [2A](#F2){ref-type="fig"}) in male pups remains unaltered; however, the expression of Gad1p in female pups from the HMFA group was significantly reduced (Figure [2B](#F2){ref-type="fig"}). In contrast, the expression of Park2p remained unchanged in both male and female pups from the HMFA group (Figures [3A,B](#F3){ref-type="fig"}). These results show that HMFA during gestation can modulate the expression of genes in offspring\'s CB and that such impact can be gender-specific.

![**Western blot analysis showing the expression of Gad1p in the cerebellum of (A) male (M) and (B) female (F) pups from LMFA (0.4 mg/kg diet) and HMFA (4 mg/kg diet) groups**. The left panel shows one representative blot, and the right panel shows the mean densitometric evaluation. The error bar ± SD represents the inter-variability among independent samples (*n* = 4). Asterisks denote statistically significant change (\*\**P* \< 0.05) by unpaired *T*-test.](fnins-10-00168-g0002){#F2}

![**Western blot analysis showing the expression of Park2p in the CB of (A) male and (B) female pups from LMFA (0.4 mg/kg diet) and HMFA (4 mg/kg diet)**. The left panel represents one representative blot, and the right panel shows the mean densitometric evaluation. The error bar ± SD represents the inter-variability among independent samples (*n* = 4).](fnins-10-00168-g0003){#F3}

Maternal FA modulates sex-specific alterations in expression of genes in the offspring\'s CB
--------------------------------------------------------------------------------------------

To gain insight into whether HMFA-induced changes in methylation profiles modulate sex-specific alterations in the expression of genes, we analyzed the expression of several genes that exhibited alterations in methylation in the opposite sex. In male pups, the expression of the genes *Coro1a, Gad1, Kcnb1*, and *Fmr1* (which exhibited changes in methylation and gene expression in female pups) was not altered (Figure [4A](#F4){ref-type="fig"}); in contrast, the expression of *Drp2, Itga2*, and *Pfn1* was altered in male pups from the HMFA group, although it exhibited no alterations in methylation profile in comparison to the LMFA group. However, the expression of the genes *Nrxn2, Col11a2, Dnmt1*, and *Rxfp2* was unaltered; while *Slc25a12*, and *Kcnq2* was altered in pups of both genders from the HMFA group. Similarly, in female pups, the expression of genes (Figure [4B](#F4){ref-type="fig"}) *Kcnk10, Cacna1g, Dock4, Gabrr1, Gabrb1, Kcnab2, Scn8a*, and *Myst4* (which exhibited changes in methylation and gene expression in male pups) was not altered, in contrast to the expression of *Gtf2i* being altered in female pups from the HMFA group, although it exhibited no alterations in methylation profile in comparison to the LFMA group. However, expression of the genes *Atp1a1, Bre, Celsr3, Kcnq4, Dcaf1*, and *Rbfox1* was unaltered in pups of both genders from the HMFA group.

![**Quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR) showing relative expression of the transcripts of genes in (A) male pups and (B) female pups from the HMFA group that exhibited no alterations in the methylation profile in promoter and gene body in the cerebellum compared with the LMFA**. The results were normalized to Hprt transcript expression and were expressed as relative values in comparison with corresponding transcripts from LMFA. Results represent mean ± standard deviation (SD); asterisks denote statistically significant change (^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001).](fnins-10-00168-g0004){#F4}

Discussion {#s4}
==========

DNA methylation in the early embryo has long been associated with the maintenance of genomic integrity, with its crucial role in modulating gene expression and genomic imprinting (Farthing et al., [@B16]; Messerschmidt et al., [@B37]). Epigenetic alterations of effectors in the developing brains of mammals can impair normal development and result in neurodevelopmental disorders (Schanen, [@B48]; LaSalle and Yasui, [@B26]; LaSalle, [@B25]). In this study, we performed genome-wide methylation analysis to test the hypothesis that exposure to HMFA during gestation induces epigenetic changes in the mouse offspring\'s CB and contributes to alterations in gene expression. We found distinct alterations in the methylation profile in The CB of offspring from mothers that received HMFA in comparison to LMFA. Such changes were widespread throughout the genome and were evident in both promoter and intragenic regions. These data establish that in addition to its role in preventing NTD\'s, FA during gestation can induce epigenetic changes in the brain.

As a pteroylmonoglutamate, FA cannot breach the blood brain barrier, with only methylfolate appearing in the cerebrospinal fluid (CSF). After FA is consumed, metabolically it is chemically reduced to tetrahydrofolate by the enzyme dihydrofolate reductase (DHFR) in the liver, where it collects a formyl group, which is reduced to methyl to form 5-methyltetrahydrofolic acid (Barua et al., [@B7]). However, excess supplementation with FA may overwhelm this process and possibly saturate the DHFR activity. Perhaps the benefit of high doses of FA may be limited by saturation of DHFR, as studies have shown that DHFR activity in human liver is extremely slow and variable (Bailey and Ayling, [@B2]). We speculate that mechanistically one possibility is that excess FA in blood may compete to bind with the folate receptor and inhibit methyl-tetrahydrofoalte transport, resulting in changes in brain homeostasis (Smith et al., [@B52]). Alternatively, elevated methylfolate via maternal metabolism may concentrate against a gradient in the CSF by the choroid plexus and thus interfere with the regulatory functions of the brain. Because the developing brain is potentially vulnerable to maternal nutrient availability (Antonow-Schlorke et al., [@B1]), such exposure to HMFA may impact the brain function of offspring with alterations in methylation and gene expression, as is evident from the data of our study.

To date, much progress has been made to characterize the dynamic changes of DNA methylation in CpG sites and its role in functional outcome. However, the research to elucidate the precise mechanism by which methylation in non-CpG sites affects gene expression and its role in functional outcomes is still in its infancy. Studies have shown that *Dnmts* have sequence specificity and can influence the methylation in non-CpG sites (Ramsahoye et al., [@B45]; Gowher and Jeltsch, [@B20]; Mund et al., [@B38]). Similar to our previous findings (Barua et al., [@B6]), the data generated from this study suggest that alterations in FA intake during gestation can modulate the methylation profile of both CpG and non-CpG sites in the brains of offspring. Our results revealed that HMFA increases the expression levels of *Dnmt3b* in male pups and of *Dnmt3a, Dnmt3b* in female pups (Figure [4](#F4){ref-type="fig"}). Such evidence supports the idea that HMFA may increase the activity of *Dnmts* which can modulate neuronal differentiation (Luo et al., [@B31]); perhaps neuronal cells have a higher variation in DNA methylation than non-neuronal cells (Zhang et al., [@B59]; Melka et al., [@B36]). This study further establishes the theory of variations in methylation of neuronal cells, with distinct methylation patterns of CpG and non-CpG sites throughout the genome, including promoters and intergenic and intragenic regions in the CB of pups from the HMFA group in comparison to the LMFA group. This finding is in agreement with our previous reports and suggests that HMFA during gestation can induce unbiased distribution of methylation in the brains of offspring. Such differences in the methylation pattern in the intragenic region may have different correlations to the expression of transcriptional levels, as is evident from our study. Indeed, studies in mammalian cells and human brains correlated changes in methylation of intragenic regions with both up-regulation and down-regulation of transcripts (Ball et al., [@B3]; Rauch et al., [@B46]; Maunakea et al., [@B35]).

Our data also highlighted that several genes that play a role in neuronal pathways exhibited alterations in expression in the CB of offspring. For example, pups from HMFA exhibited significant changes in the expression of several voltage-dependent ion channels (*Cacna1g, Scna8a, Kcnk10, Kcnab2, Kcnq1, Kcnq2*), which may result in modulation in neuronal synaptic transmission and excitability (Vacher et al., [@B56]).

Similarly, several genes (*Grik4, Gabrr1, Gabrg3, Gabrb1*, and *Gad1*) involved in GABAergic (gamma-aminobutyric acid) or glutamatergic synaptic transmissions exhibited alterations in expression in pups from HMFA. Studies have reported that GABAergic interneurons play a central role in the modulation of excitatory output in the brain and have been documented with a wide variety of psychiatric diseases, including mood disorders, schizophrenia and autism (Fatemi and Folsom, [@B17]). Biochemical studies have revealed that the expressions of GAD65/67 are decreased in the CB of subjects with developmental disorders such as autism and schizophrenia (Bullock et al., [@B11]; Blatt and Fatemi, [@B9]). In the current study, we found that HMFA decreased the expression of Gad1p in female pups, where the expression in the male pups remains unaltered.

Such alterations in the expression of Gad1p may induce alterations in learning and social behavior, as studies with Gad67-deficient mice have been reported to exhibit behavioral abnormalities and reduced sociability (Sandhu et al., [@B47]; Zhang et al., [@B60]). Indeed, our previous studies showed that gestational and post-weaning HMFA resulted in changes in behavior, with an increase in ultrasonic vocalization as neonates (Barua et al., [@B4]). Such findings indicate that maternal nutritional status, specifically variations in the methyl diet, can induce changes in DNA methylation and thus modulate the expression of genes involved in neuronal pathways and may impact the behavioral outcomes.

Off note, neuronal cells are found to exhibit more inter-individual variations compare to non-neuronal cells (Iwamoto et al., [@B23]). Moreover, studies with post-mortem brain samples from patient with major depression have shown significant cell specific epigenetic variation in between brain regions (Guintivano et al., [@B22]). One of the limitations of our current study is that we used the whole cerebellum from pups for methylation and expression analysis; thus some of the alterations of DNA methylation profile may results due to cellular heterogeneity.

Previous studies have reported sexual dimorphism and asymmetry in animal and human cerebellum (Ramirez and Jimenez, [@B44]; Fan et al., [@B15]). It is also reported that perinatal exposure to chemical and physical perturbations impact differential neurodevelopment and behavioral effects in males and females (Nguon et al., [@B39]); other studies with mouse placenta have shown that maternal diet impacts gene expression differentially in males and females (Mao et al., [@B32]; Gabory et al., [@B18]). Our data also shows a significant bias between genders in methylation and expression of genes in the offspring CB as a result of HMFA. This finding is congruent with our previous report that HMFA induces gender-specific methylation changes in the brains of offspring (Barua et al., [@B6]). We speculate that such differential methylation could results from alterations in the uterine environment because of excess FA, and biased sensitivity to nutritional perturbations resulted from gender specific distribution of specific receptors and methylation of imprinted genes.

Conclusions {#s5}
===========

Given the role of maternal FA in the methylation pathway, it remains an open questions how such epigenetic modifications impact the brain and behavior of offspring. Our findings support the idea that epigenetic variations may have distinct sex biased functional consequences to certain neuropsychiatric disorders. It further highlights the relevance of studying both sexes in both experimental model and clinical studies to study the epigenetic impact of maternal diet.

In summary, a key finding of this study is that FA during gestation, aside from its role in preventing NTDs, can induce alterations in the methylation of several genes in both CpG and non-CpG regions in the offspring\'s CB, and such alterations in methylation are gene- and sex- specific. Such changes in DNA methylation during gestation can induce alterations in gene regulatory structures, and given the role the CB in regulation of higher order functions, including motor function and cognition (Schmahmann, [@B49]; Tavano et al., [@B55]), such changes may modulate the functional outcome of neurologic and psychiatric diseases.
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**Distribution of differentially methylated sites in CpG island sequences. (A)** Male; low maternal folic acid (LMFA) vs. high maternal folic acid (HMFA). **(B)** Female LMFA vs. HMFA.

###### 

Click here for additional data file.

###### 

**Distribution of differentially methylated sites in non-CpG (CHG/CHH) sites of cerebellum. (A)** Male low maternal folic acid (LMFA) vs. high maternal folic acid (HMFA). **(B)** Female LMFA vs. HMFA.

###### 

Click here for additional data file.

###### 

**Scatter plot representing the distribution of the methylation ratio for corresponding sites (A) CpG, (B) CHG, and (C) CHH of LMFA vs. HMFA of male pups**. Pearson\'s correlation coefficient is denoted in the center of each scatter plot.
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Click here for additional data file.

###### 

**Scatter plot representing the distribution of the methylation ratio for corresponding sites (A) CpG, (B) CHG, and (C) CHH of LMFA vs. HMFA of female pups**. Pearson\'s correlation coefficient is denoted in the center of each scatter plot.
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Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

**Hexbin plot representing the overlapped sites in the CpG (***n*** = 2715), CHG (***n*** = 111), and CHH (***n*** = 192) regions between male and female pups from the HMFA group in comparison with the LMFA group from all the significant (***P*** \< 0.05) differential methylation sites**. Each dot on hexbin plot is one of the overlapped sites. The colors blue, green, yellow and red represent the dot density from lower to higher order, in accordance with the prevalence of the overlapping sites.
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Click here for additional data file.

###### 

**Genes in male offspring from high maternal folic acid (HMFA) diet, which exhibited hyper methylation (***P*** \< 0.05) compared with genes in male offspring from low maternal folic acid (LMFA) in CpG/CHG/CHH contexts**.

###### 

Click here for additional data file.

###### 

**Genes in male offspring from high maternal folic acid (HMFA) diet, which exhibited hypo methylation (***P*** \< 0.05) compared with genes in male offspring from low maternal folic acid (LMFA) in CpG/CHG/CHH contexts**.

###### 

Click here for additional data file.

###### 

**Genes in male offspring from high maternal folic acid (HMFA) diet, which exhibited hyper methylation (***P*** \< 0.05) compared with genes in female offspring from low maternal folic acid (LMFA) in CpG/CHG/CHH contexts**.

###### 

Click here for additional data file.

###### 

**Genes in male offspring from high maternal folic acid (HMFA) diet, which exhibited hypo methylation (***P*** \< 0.05) compared with genes in female offspring from low maternal folic acid (LMFA) in CpG/CHG/CHH contexts**.

###### 

Click here for additional data file.

###### 

**List of primers used in this study**.

###### 

Click here for additional data file.

FA

:   Folic acid

NTDs

:   Neural tube defects

LMFA

:   Low maternal folic acid

HMFA

:   High maternal folic acid

5 mC

:   5-methylcytosine

CB

:   Cerebellum.
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